vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Apellis Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($199.9M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). Axsome Therapeutics, Inc. runs the higher net margin — -14.6% vs -29.5%, a 14.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -5.9%). Apellis Pharmaceuticals, Inc. produced more free cash flow last quarter ($-14.3M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
APLS vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $196.0M |
| Net Profit | $-59.0M | $-28.6M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | -13.8% |
| Net Margin | -29.5% | -14.6% |
| Revenue YoY | -5.9% | 65.0% |
| Net Profit YoY | -62.2% | 61.9% |
| EPS (diluted) | $-0.40 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $196.0M | ||
| Q3 25 | $458.6M | $171.0M | ||
| Q2 25 | $178.5M | $150.0M | ||
| Q1 25 | $166.8M | $121.5M | ||
| Q4 24 | $212.5M | $118.8M | ||
| Q3 24 | $196.8M | $104.8M | ||
| Q2 24 | $199.7M | $87.2M | ||
| Q1 24 | $172.3M | $75.0M |
| Q4 25 | $-59.0M | $-28.6M | ||
| Q3 25 | $215.7M | $-47.2M | ||
| Q2 25 | $-42.2M | $-48.0M | ||
| Q1 25 | $-92.2M | $-59.4M | ||
| Q4 24 | $-36.4M | $-74.9M | ||
| Q3 24 | $-57.4M | $-64.6M | ||
| Q2 24 | $-37.7M | $-79.3M | ||
| Q1 24 | $-66.4M | $-68.4M |
| Q4 25 | -25.6% | -13.8% | ||
| Q3 25 | 48.7% | -27.0% | ||
| Q2 25 | -18.6% | -24.5% | ||
| Q1 25 | -50.0% | -46.9% | ||
| Q4 24 | -12.3% | -61.1% | ||
| Q3 24 | -24.0% | -59.8% | ||
| Q2 24 | -14.7% | -89.5% | ||
| Q1 24 | -36.0% | -89.7% |
| Q4 25 | -29.5% | -14.6% | ||
| Q3 25 | 47.0% | -27.6% | ||
| Q2 25 | -23.6% | -32.0% | ||
| Q1 25 | -55.3% | -48.9% | ||
| Q4 24 | -17.1% | -63.1% | ||
| Q3 24 | -29.2% | -61.7% | ||
| Q2 24 | -18.9% | -91.0% | ||
| Q1 24 | -38.5% | -91.1% |
| Q4 25 | $-0.40 | $-0.55 | ||
| Q3 25 | $1.67 | $-0.94 | ||
| Q2 25 | $-0.33 | $-0.97 | ||
| Q1 25 | $-0.74 | $-1.22 | ||
| Q4 24 | $-0.30 | $-1.54 | ||
| Q3 24 | $-0.46 | $-1.34 | ||
| Q2 24 | $-0.30 | $-1.67 | ||
| Q1 24 | $-0.54 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | $88.3M |
| Total Assets | $1.1B | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | $322.9M | ||
| Q3 25 | $479.2M | $325.3M | ||
| Q2 25 | $370.0M | $303.0M | ||
| Q1 25 | $358.4M | $300.9M | ||
| Q4 24 | $411.3M | $315.4M | ||
| Q3 24 | $396.9M | $327.3M | ||
| Q2 24 | $360.1M | $315.7M | ||
| Q1 24 | $325.9M | $331.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $88.3M | ||
| Q3 25 | $401.2M | $73.7M | ||
| Q2 25 | $156.3M | $73.1M | ||
| Q1 25 | $164.2M | $53.2M | ||
| Q4 24 | $228.5M | $57.0M | ||
| Q3 24 | $237.1M | $92.9M | ||
| Q2 24 | $264.3M | $102.9M | ||
| Q1 24 | $266.7M | $144.0M |
| Q4 25 | $1.1B | $689.8M | ||
| Q3 25 | $1.1B | $669.3M | ||
| Q2 25 | $821.4M | $639.8M | ||
| Q1 25 | $807.3M | $596.7M | ||
| Q4 24 | $885.1M | $568.5M | ||
| Q3 24 | $901.9M | $561.5M | ||
| Q2 24 | $904.5M | $548.2M | ||
| Q1 24 | $831.9M | $545.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $-18.7M |
| Free Cash FlowOCF − Capex | $-14.3M | $-18.7M |
| FCF MarginFCF / Revenue | -7.1% | -9.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | $-18.7M | ||
| Q3 25 | $108.5M | $1.0M | ||
| Q2 25 | $4.4M | $-32.4M | ||
| Q1 25 | $-53.4M | $-43.4M | ||
| Q4 24 | $19.4M | $-26.2M | ||
| Q3 24 | $34.1M | $-18.6M | ||
| Q2 24 | $-8.3M | $-30.1M | ||
| Q1 24 | $-133.0M | $-53.5M |
| Q4 25 | $-14.3M | $-18.7M | ||
| Q3 25 | $108.3M | $988.0K | ||
| Q2 25 | $4.4M | $-32.4M | ||
| Q1 25 | $-53.4M | $-43.7M | ||
| Q4 24 | $19.3M | $-26.2M | ||
| Q3 24 | — | $-18.7M | ||
| Q2 24 | $-8.4M | $-30.2M | ||
| Q1 24 | $-133.3M | $-53.6M |
| Q4 25 | -7.1% | -9.6% | ||
| Q3 25 | 23.6% | 0.6% | ||
| Q2 25 | 2.5% | -21.6% | ||
| Q1 25 | -32.0% | -36.0% | ||
| Q4 24 | 9.1% | -22.1% | ||
| Q3 24 | — | -17.9% | ||
| Q2 24 | -4.2% | -34.6% | ||
| Q1 24 | -77.3% | -71.4% |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
AXSM
Segment breakdown not available.
